NRG B-52

Primary Category:

Treatment Protocols

Disease Category:

Breast, Breast Neoadjuvant

Status:

Closed

A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation

 

B-52 will close to accrual, today, February 29, 2016, effective 8 pm EST. We realize that some patients who have consented to participate in the study will not have completed their pre-entry biopsy to obtain fresh tumor samples by today; therefore, patients who have signed the B-52 consent form on or before today, February 29, 2016, will be permitted to enter the study.

NCT#02003209

Leave a Reply